RFP QuestBeta
Awarded · ResultStage · award

NHS England

NHS National Framework for Transition Products (Nintedanib and Dalbavancin)

ValueValue not published
Awarded
Published24 Apr 2026
RegionNationwide
Outcome — awarded
ZENTIVA PHARMA UK LIMITED + 5 more

This is a contract result notice, not an open opportunity. Details from the official award data.

Who to contact
katie.noonan@nhs.net

The procurement contact named on the official notice.

The brief

Project title: NHS National Framework for Transition Products (Nintedanib and Dalbavancin) commencing 1st May 2026 Offer reference number: CM/TNS/25/5736 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months.

CM/TNS/25/5736 Nintedanib and Dalbavancin Lot 1 DLN/DNW: 01/05/2026 to 30/09/2027 (17 months) Lot 2 DLS/DNE: 01/05/2026 to 31/05/2027 (13 months) Lot 3 DCE/DSW: 01/05/2026 to 31/01/2027 (9 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Key requirements

What the supplier must deliver

01

Published By: Medicines Procurement and Supply Chain

Published By: Medicines Procurement and Supply Chain.

Derived from the notice text — always confirm against the original documents.

Buyer intelligence

Make the case to bid

Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.

Source & provenance
OCID
ocds-h6vhtk-05d361
Stage
award · Awarded
Source
Find a Tender
Buyer ref
037405-2026
View the original notice on Find a Tender

Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.

Market context

Who wins this kind of work

The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.

NHS England’s tender network

Assembling the network…